Actively Recruiting
Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
Led by Janux Therapeutics · Updated on 2026-04-23
60
Participants Needed
1
Research Sites
41 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This first-in-human (FIH) study aims to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JANX011 dosed subcutaneously (and potentially intravenously) in healthy adult volunteers (HVs) to gain insight into its therapeutic utility in patients with autoimmune diseases.
CONDITIONS
Official Title
Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy men and women as determined by physical exam, lab tests, and medical history
- Aged 18 to 65 years
- Body weight between 50 and 120 kg
- Body mass index (BMI) between 18 and 32 kg/m2
- Able and willing to provide written informed consent
You will not qualify if you...
- Recent surgery requiring general anesthesia within 12 weeks prior to screening or planned during the study
- Positive test for hepatitis C antibody, hepatitis B surface antigen, HIV-1 or HIV-2 antibodies
- Positive test for tuberculosis or history of tuberculosis
- Use of any investigational drug or medical device within 30 days or 5 half-lives prior to dosing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CMAX
Adelaide, South Australia, Australia, 5000
Actively Recruiting
Research Team
J
Janux Therapeutics
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here